Human insulin produced in Bacteria is already a miracle for Diabetes…but sometimes, it’s not as efficient as it could be. The French Biotech Adocia is developing a super-insulin and showed successful efficiency data in a early-stage human trials.
Adocia is a Lyon-based Biotech we have discussed before. Even if its logo is a bit strange (looks like a zombie no?) it has been extremely successful in the last few years in chronic disease. For example, Adocia signed a massive €464M deal with Eli Lilly on one of its diabetes programs. Its technology, BioChaperone, enhances the properties of human proteins, and are typically focused on insulin. The company is now worth a bit over €500M on the Paris Stock Market and today counts around 100 employees.
The company tested Eli Lilly’s Humalog75/25 alone and compared to the BioChaperone Combo (mix of two different insulin types) in 28 patients with type 1 diabetes. The goal was to observe the effect on post-meal glycemic control. The study met its objectives and demonstrated superiority in reduce post-meal blood glucose over the standard treatment of Eli Lilly.